. Archives of Disease in Childhood, 48, 856. Betamethasone 17-valerate by aerosol in childhood asthma. A double-blind cross-over trial of betamethasone 17-valerate (B17V) administered by aerosol was carried out by alternating two placebo periods with two treated periods at monthly intervals in 20 children with severe asthma. During the trial, the average of twice-daily peak expiratory flow readings was significantly increased in every child during actively treated months, compared with placebo months. Every child had fewer symptoms while using B17V, and the average reduction for the group as a whole was 71 %. Very much less additional medication for asthma was required during months of active treatment. The observed clinical response to therapy was dramatic in over half the children. No side effects were noted. Under the conditions of this study, we conclude that B17V by aerosol appears to be safe, and is effective for the control of asthma in children.
The efficacy of orally administered steroid preparations for the control of asthma is such that they would be universally used were it not for their undesirable side-effects when administered in pharmacological doses. These include manifestations of Cushing's syndrome, suppression of the pituitary-adrenal axis, and stunting of growth in children. The unwillingness of physicians to drop such valuable therapy has led to a search for a means of retaining pharmacological properties, while reducing either the dose or the side-effects of steroid compounds: for example, by using an alternative method of administration.
There is a theoretical advantage in delivering the drug direct to the bronchial tree, where it might be expected to exert a local action at much lower doses than are needed orally. Early work with inhaled hydrocortisone and prednisolone powders (Brockbank and Pengelly, 1958;  Herxheimer, McAllen, and Williams, 1958) and with metered aerosol (Franklin et al., 1958) showed results which seemed encouraging, but proved disappointing because of the high dosage required. Dexamethasone by aerosol in adults (Fisch and Grater, 1962;  Arbesman, Bonstein, and Reisman, 1963) and in children (Siegel et al., 1964; Kravis and Lecks, Received 2 May 1973. 1966) proved to be an effective method of controlling asthma, but the drug was absorbed in amounts sufficient to give systemic effects.
New interest has been aroused in this field since it has become apparent that steroids with a high index of topical activity, but relatively low adrenal suppressive action, may prove both clinically effective and systemically harmless. The compounds betamethasone 17-valerate (B17V) and beclomethasone dipropionate fall into this group.
Work with the latter (Lal et al., 1972; Brown, Storey, and George, 1972; Clark, 1972; Choo-Kang et al., 1972) has indicated a good clinical response, though the interpretation of pituitary-adrenal function tests carried out on patients using the aerosol has been complicated by the fact that many of them had been previously maintained on longterm oral steroids at suppressive doses.
Previous experience of B17V has been limited mainly to the treatment of skin conditions (as Betnovate). Absorption through the skin in amounts sufficient to cause adrenal suppression has occurred, but only when 30 g/day was applied to 60% of the body surface under polyethylene occlusion in patients with acute dermatoses (James, Munro, and Feiwel, 1967) . When used as a retention enema in the treatment of distal proctocolitis, 5 mg B17V daily was found to be as Betamethasone 1 7-valerate by aerosol in childhood asthma effective as 20 mg prednisolone 21-phosphate, and caused less suppression (Multicentre Trial, 1971) . As a nasal spray it is effective for allergic rhinitis (Czarny and Brostoff, 1968) . 1 patient out of 12 using 0 4 mg B17V intranasally for 7 days showed evidence of adrenal suppression.
The aim of the present trial was to show that B17V is effective in the control of chronic or frequently recurrent asthma. In this notoriously capricious disease, where subjective observations are inevitably influenced by placebo response and spontaneous remissions, assessment can only be properly made through a double-blind cross-over study. An attempt was made to assess the effect on the pituitary-adrenal axis by serial cortisol estimations throughout the trial. Method Subjects. 22 children were selected from the Whittington Hospital paediatric asthma clinic on the following criteria. (a) Their symptoms conformed with the definition of asthma by Scadding (1966) At the outset of the trial, in order to reassure the patient when symptoms flared up on placebo therapy, it was explained that the aerosols would contain two different drugs, one of which might be more effective than the other. Patients did not know the periodicity of the sequence of aerosols, which were renewed once a fortnight. Mothers were told that the drug would act by preventing the child from getting asthma, and not by immediate relief of symptoms, and were reassured that every additional medication required to control the child's symptoms would be given throughout the trial period. They were instructed to continue the medication the child was having before the trial. No attempt was made to wean the patient off any other drugs unless the asthma chart showed a score of 0 for at least 4 days previously, and then maintenance medication was discontinued one drug at a time over the course of the next few days. Disodium cromoglycate (DSCG) (Intal) was the last drug to be discontinued. When symptoms recurred, all the previous medication with the exception of DSCG was re-introduced until another clear 4-day period occurred.
During the first month of the trial patients were seen weekly, and thereafter at fortnightly intervals. At each attendance height, weight, forced expiratory volume at one second (FEV,), and peak expiratory flow rate (PEF) were recorded, and a subjective assessment of clinical state was made by parent and physician on a basis of same/better/worse than the period before the last visit. Blood for plasma cortisol was taken at fortnightly intervals wherever possible and an estimation was made by the fluorimetric method of Mattingly (1962) . At the end of the trial, the patient's mother and the physician recorded their impressions of each month in turn.
Results
The results of 20 of the 22 children who were started in this trial are presented. One patient failed to attend regularly, and the other was withdrawn from the trial because she became so ill in a placebo month that the code was broken to see whether she had benefited from active treatment.
The 20 children whose results were analysed included 13 boys and 7 girls with a mean age of 8 years 7 months (range 4 years 6 months-14 years 11 months). 11 patients received B17V and 9 received placebo in the first trial month. The results of 2 representative patients are presented in Fig. 1 and 2 . In view of the variable nature of the disease, it has been recently pointed out (Silverman et al., 1972) Shov ing daily asthma symptom score, twice-daily peakflow readings, and asthma therapy immediately before and during trial in a boy aged 1 years 5 months who had had asthma since 6 years of age. Hay fever; no hospital admissions or steroid therapy. Chest deformity; 28% eosinophilia; family history of atopy; addicted to medihaler-iso aerosol, taking 50 doses overnight in last bad attack.
months in 19 out of 20 children, 1 patient being considered too young to use a peak flow meter properly.
When the average twice-daily readings for the two 28-day placebo periods was compared with the average of the two 28-day treated periods (Table I and Fig. 3) , each child showed an increase. This ranged from 3 % to 85%, with a mean of 31%'o.
Compared with the average over the pretrial run, which was carried out over a shorter time span (16 days average, range 7-27), peak flow readings during the treated period were again higher. 9 children averaged above their lowest predicted normal value (-2 SD) (Weng and Levison, 1969) during active treatment. In 3 cases, readings done before the trial started were higher than during the placebo period, reflecting the variability of symptoms in asthma. In the remaining 16 of the 19 children, the pretrial average was comparable to, or lower than, the placebo average. Changes in symptom score. Every patient had a lower average monthly symptom score during treatment with B17V than during the placebo period (Fig. 4) order to exclude any carry-over effect from the previous month, the periods selected for comparison were the last 7 days of each trial month. Average bronchodilator intake on placebo was 83% of pretrial requirements, and on B17V it fell to 34%. Of the 8 children on DSCG at the start of the trial, 7 had discontinued it by the end. Only 1 child appeared to be worse after stopping it.
Two children were using pressurized bronchodilator aerosols for relief of symptoms before the trial, and 1 was dangerously addicted, so that in a recent severe attack he had taken 50 doses overnight. 1 of these 2 did not use the bronchodilator aerosol at all in the active months of the trial, and the addict was only taking very occasional doses (Fig. 2) as opposed to heavy usage in placebo periods. Both children handed in their bronchodilator aerosols shortly after the end of the trial, when they were maintained on long-term B17V.
Over the 4-month period, 121 aminophylline suppositories were used by 13 children, 110 in placebo months and 11 during B17V months, mainly in the first 3 days before the drug had achieved maximum effect. Two children required short courses of prednisolone during placebo months.
Observations made in the asthma clinic. Clinical observations usually followed the pattern of the trial, and by the end the response was so clear in 11 cases that the physician was able to make a confident correct guess about the arrangement of months. 11 mothers volunteered a remark to the effect that their child had never been so well since the onset of asthma, and always in reference to a treated period. The remaining 9 children had a less clear-cut response, but the tentative guess made by the physician about the order of the trial was nevertheless always correct.
Serial cortisol estmations. Taking a normal level as 5 ,ug/100 ml or above, 6 children (Cases 1, 2, 3, 15, 16, 20) had low levels at some time during active treatment (Table III) . However, in 4 of these patients the levels were subsequently normal while still on active treatment. In 2 patients in whom low values were obtained, only a single estimation was made. 2 patients (Cases 3 and 15) had had previous steroid therapy, which may account for the low values. In 2 (Cases 2 and 15) an intravenous insulin tolerance test and tetracosactrin test (Wood et al., 7,9 5 9, 13, 8,10 7,17,9,8, 6 6 7,8,7,8 7,9,8, 10,7 7 18, 17, 20 11, 16, 9, 24, 14 8 10 Fig. 1 . No factors came to light in judging who will respond to this form of therapy, and it appeared that the age of the child was irrelevant provided he was old enough to use a pressurized aerosol, which in practice turned out to be above 6 years, with the exception of the youngest child aged 4 years 6 months whose mother, herself an aerosol user, was able to hold the aerosol and time the administration correctly. The children who responded least well tended to be those with disturbed family relationships, one important factor possibly being lack of supervision over medication.
The majority of children in this group came from atopic families and suffered from early onset asthma, usually preceeded by eczema. Many had had multiple hospital admissions. One had in the past required maintenance therapy with prednisone for 3 years, and 3 others had had intermittent courses of ACTH and/or oral steroids. 19 were currently on routine conventional therapy with or without DSCG. These children all had fairly severe asthma interfering with their daily lives, and were on the whole candidates for oral steroid or ACTH maintenance treatment. Some of them showed the nutritional effects of chronic asthma, which tended to improve during the trial.
No clinical side effects of excess glucocorticoid activity were observed during the trial, and from results of plasma cortisols so far it is uncertain whether there is suppression of the pituitary-adrenal axis. It seems unlikely, since we have administered 1600 ,ug daily to adult volunteers for 7 days and have found no evidence of suppression of the hypothalamic-pituitary-adrenal axis (J. F. Frears and M. Friedman, unpublished data). The total dose administered by aerosol would, if given orally, be insufficient to cause suppression (Friedman et al., 1967) .
